Immune potency of recombinant adeno-associated virus combined with recombinant adenovirus vaccine containing HIV-1 gp120.
- Author:
Xia FENG
1
;
Shuang-qing YU
;
Guo-min CHEN
;
Xiao-bing WU
;
Jian-min ZUO
;
Wen-ping DONG
;
Ling ZHOU
;
Yi ZENG
Author Information
- Publication Type:Journal Article
- MeSH: Adenoviridae; genetics; Animals; CD8-Positive T-Lymphocytes; immunology; Dependovirus; genetics; Female; Genetic Vectors; HIV Envelope Protein gp120; biosynthesis; genetics; immunology; HIV-1; Immunoglobulin G; blood; Interferon-gamma; blood; Mice; Mice, Inbred BALB C; Plasmids; Recombination, Genetic; T-Lymphocytes, Cytotoxic; immunology; Vaccines, DNA; immunology; metabolism
- From: Chinese Journal of Experimental and Clinical Virology 2004;18(4):312-315
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the immune effect of recombinant adeno-associated virus (rAAV) combined with recombinant adenovirus (rAdV) vaccine in BALB/c mice.
METHODSThe codon-modified HIV-1 gp120 gene was inserted into plasmid of adeno-associated virus and adenovirus vector separately. Then the rAAV and rAdV vaccines were constructed. BALB/c mice were immunized with rAAV and rAdV vaccines in different administration scheme. The IgG antibody was detected by ELISA and CTL response was detected by intracellular cytokine stain assay.
RESULTSBoth rAAV and rAdV vaccine could express gp120 gene; the mice primed with rAAV at week 0, 2 and boosted with rAdV at week 5, 14 and 20 elicited the strongest gp120 specific CTL and IgG antibody response.
CONCLUSIONThe mice primed with rAAV and boosted with rAdV could elicit specific CTL response and IgG antibody.
